High-Yield Mesenchymal Stem/Stromal Cell Expansion is Advancing Cell Therapy | MSC Manufacturing Developments

High-Yield Mesenchymal Stem/Stromal Cell (MSC) Expansion at the Forefront of Cell Therapy Advancement

Advancements in cell therapy driven by mesenchymal stem/stromal cells (MSCs) are rapidly advancing from initial therapeutic trials into routine clinical use. As indications expand and products transition from autologous to allogeneic, the key question is no longer whether MSCs are an effective therapeutic tool, but rather how to reliably and efficiently harness the power of MSC expansion to produce enough high-quality cells to meet the rigors of clinical and commercial demands.

We spoke with Hilary Sherman, Senior Applications Scientist at Corning, to discuss current developments in MSC manufacturing. The focus was on three key areas and themes that significantly influence the successful upscaling of high-yield MSC expansion: scalability, reproducibility, and efficacy as well as the strategies needed to reduce risks in cell therapy manufacturing.

Why High-Yield MSC Expansion Matters

MSC products offer several valuable innate therapeutic benefits and exert strong immunomodulatory and regenerative effects via paracrine signaling. Other top beneficial cellular features of MSCs include their ability to be derived and sourced from numerous tissue types (adipose, bone marrow, umbilical cord) and their relatively low immunogenicity. Unlike induced pluripotent stem cells (iPSCs), MSCs also inherently have a lower tumorigenic risk. They have immunomodulatory properties that iPSCs lack and are much easier to isolate and culture than iPSCs.

However, these biological strengths do not fully eliminate the manufacturing challenges inherent in scaling up high-yield cell expansion. Sherman noted that some early MSC applications, such as local injections and wound-healing applications, required relatively few cells while newer indications can require much higher cell doses, sometimes even multiple doses. MSC products often require tens of billions of cells per batch, if not more, derived from relatively smaller donor samples. Variability between donors, inherent limitations in expansion capacity, and sensitivity to culture conditions significantly decrease cellular potency and consistency.

As a result, developers now need far more MSCs than previously required, creating a need for more tools to meet the increased cellular demand. High-yield MSC expansion is where scientific ambition meets factory-floor reality, where the cellular growth process must produce more cells per run, per square centimeter, and per operator hour without compromising cell quality or drastically increasing precious lab space.

These imperatives shape and drive the design priorities for integrated vessel and media platforms to maximize growth area, nutrient delivery, and process control. As MSC manufacturing continues to develop, scientists and researchers still encounter a wide range of scale-out challenges that involve both operational and biological hurdles.

Corning addresses these interconnected risks through a collaborative partnership model, offering practical guidance to help teams align biological processes with regulatory requirements to develop robust, end-to-end workflows. These workflows span from early process development and vessel selection to scale-out, closed-system design and readiness for commercial manufacturing, incorporating strategies.

From Bench to Bedside: Vessel Platforms That Scale with You

Therapeutic-scale MSC manufacturing requires far more cells than standard flasks and dishes can efficiently and reliably produce. Unfortunately, scaling by adding more flasks quickly increases the incubator footprint, labor, and the risk of variability.

Access the Whitepaper

Complete this short form to access the Whitepaper: Producing MSC-derived Cell Therapies from Isolation to Large-scale Expansion

A journey of workflows, technologies, and case studies from our Field Application Scientists. 

More Cells, Same Footprint: Enhancing Yield with High-Area Vessels

While traditional cell culture flasks and dishes are reliable for day-to-day MSC research, they can’t yet account for the cell numbers that are needed for clinical applications. As capacity increases in traditional cell culture models, this can only be achieved by adding more vessels, which requires more incubator space.

Novel technologies like stacked vessels address this by concentrating growth surface area into a smaller volumetric space. Multi-layer vessels, such as Corning’s CellSTACK® chambers, consolidate surface area and streamline routine tasks like feeding and harvesting, supporting early scale-out. This platform also scales with the user. Process development may start with a one-layer cell stack of 636 cm2 and eventually scale up to a 40-layer system, with each vessel consisting of 25,440 cm2 of cell culture volume. As programs grow into allogeneic pipelines and multiple indications, higher-density planar formats become more practical.

Another space-saving innovation is Corning’s® HYPERFlask®, which is engineered with reduced headspace due to its gas-permeable layers. This allows for significantly more surface area in a smaller volumetric footprint. It also has the advantage of higher-density, multi-layer formats that stack multiple gas-optimized planar layers within a single enclosed module. Standardized surface options, such as Corning’s CellBIND®, across all cell culture vessels ensure surface continuity. It incorporates a net negative charge in the cell culture surfaces, making them more wettable and facilitating better cell attachment and growth from early development through later optimization.

Corning® HYPERStack® vessels further extend this benefit through the addition of 12-layer and 36-layer configurations, which deliver thousands of square centimeters of growth area. According to Sherman, HYPERStack vessels provide a very high cell growth surface area (up to ~18,000 cm² per vessel) while maintaining a footprint that fits easily into standard incubators. This allows many high-density vessels to run in parallel without requiring additional incubator space.

In recent years, the increasing demand for MSCs to support large-scale therapeutic applications has prompted developers to explore alternatives with higher cell surface areas and more automated systems. The Corning CellCube® modules represent a promising solution for achieving high-yield MSC expansion in a compact footprint while offering enhanced process control. The CellCube-100 module, with an impressive surface area of 85,000 cm², can be combined with up to four other modules in a single batch to deliver a total growth area of 340,000 cm². This scalability, paired with its small physical footprint, makes the CellCube system another efficient tool for meeting the demands of clinical and commercial cell production.

What sets the CellCube system apart is its ability to combine the characteristics of stack vessel culture with the advantages of a bioreactor system. This integration enables better control of critical process parameters, such as nutrient delivery, gas exchange, and waste removal while also facilitating the harvest process. The modular design also supports consistent workflow execution and minimizes operator variability, making it ideal for high-throughput manufacturing. Since cells are cultivated within enclosed modules, the CellCube system offers a strategic advantage for exosome production, providing a controlled environment to maximize the yield and quality of these valuable therapeutic components. As MSC therapies continue to expand, the CellCube system provides an innovative and scalable solution to optimize both cell and exosome production aligned with the Corning closed-system solution.

Closed System Readiness: Making Tech Transfer and Scale-Out Predictable

Open handling steps significantly increase contamination risk and introduce operator-dependent variability, making this a pivotal and key barrier to consistent execution and reliable batch results as programs advance toward clinical and commercial manufacturing.

Fewer Touches, Fewer Failures: Completing the Loop in MSC Manufacturing

Closed-system workflows support process control by reducing environmental exposure and operator-dependent variability, enabling more consistent execution in clinical and commercial MSC manufacturing. In closed systems, feeding, sampling, and harvesting happen through integrated fluid paths, reducing open manipulations, which improves operational procedures and eases method transfer between teams or facilities.

"We're reducing risk by reducing handling, contamination risk, and failure points with our closed system, scalable vessels," Sherman explained.

As teams move from small research setups using open flasks and cell culture dishes to true manufacturing scale, they must prioritize scalable vessels and closed cell culture systems to meet yield requirements and reduce process challenges. Corning closed-system solutions enable aseptic MSC manufacturing at scale by minimizing contamination risk and supporting cGMP compliance. Using sterile, single-use tubing and aseptic connectors, these systems streamline fluid handling—reducing cleanroom complexity, operator exposure, and process risk while maintaining flexibility. Corning offers both off-the-shelf options and custom-configurable solutions for any process needs.

Formulation Matters: Media by Design for High-Output MSC Expansion

Media can be a forgotten, often unseen factor that significantly affects yield consistency and final product quality. Additionally, frequent media exchanges or coatings for cell attachment increase handling complexity and process variability. Batch-to-batch inconsistency in media and media supplements can also affect cellular performance and growth.

Scaling Begins in the Bottle: Media Choices That Influence MSC Yield

Media selection directly and dramatically affects cell expansion rates, senescence pathways, and functional properties important for therapy. As programs move toward clinical use, preference shifts to xeno-free or chemically defined media that better meet rigorous regulatory standards while supporting strong proliferation.

"The beauty of this media formulation is that we get higher cell expansion compared to many of the commercially available media out there," Sherman said. "So, the cells are proliferating faster, and you can get more cells out of a particular passage or vial. Additionally, the cost of the media decreases significantly because you do not need to perform a media exchange."

Corning’s MSCulture Max media supports MSC expansion across different development stages, offering research-grade, xeno-free, and xeno-free GMP-grade options. In internal scale-out evaluations, MSCulture Max-XF media enabled higher cell yields per passage while reducing the number of media exchanges, simplifying handling during expansion. Additionally, when MSCs are cultured with Corning’s MSCulture Max™ media, no coating of cell culture vessels is required. The xeno-free formulation supports translation from research into clinical manufacturing through research and xeno-free formats. Xeno-free MSCulture Max™ media is also available in a GMP-grade version.

Integrated MSC Scale-Up: Prevent Process Drift from Bench to Manufacturing

An integrated MSC expansion workflow encounters issues when vessels, media, and handling steps are treated interchangeably. As you scale up, changes in surface chemistry, media formulation, and the number of open manipulations can alter growth kinetics, cell function, increase run-to-run variability, and increase batch-failure risks. Regulators also expect evidence of process control from cell sourcing and banking through expansion and harvest, not just at final release.

The choice of vessel surface—treated, coated, or otherwise optimized—directly impacts cell behavior, senescence, and therapeutic potential. Corning addresses this by pairing consistent surface chemistry with optimized media design, reducing variability and minimizing the need to redevelop processes when scaling.

Corning Helps Bridge Research and Production

As advancements in MSC cell therapies progress, developers, scientists, and researchers will increasingly push the boundaries of MSC technology's therapeutic potential. High-yield MSC expansion is more than just process optimization; it is crucial for making next-generation therapies available on a commercial scale. Platforms such as HYPERStack vessels and MSCulture Max media show how the careful engineering of culture systems can transform expansion into a predictable, efficient, and scalable process. When vessel architecture, media design, and workflow strategy are aligned, MSC cell culture efforts are better positioned to move promising bench data into reliable clinical therapies that significantly impact patient outcomes and quality of life.

Visit our resource library to explore Corning's work with MSCs and other helpful bench-side insights.